Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Identification of risk factors for gastrointestinal irAEs associated with immune checkpoint inhibitors.
Authors
Ryo Morikawa
Clinical Oncology, Tokyo Medical and Dental University, Tokyo, Japan;
Ryo Morikawa , Kentaro Nitta , Shuntaro Yasuda , Rika Noji , Yoshihito Kano , Shingo Sato , Sadakatsu Ikeda , Masashi Nagata , Takehiko Mori , Mitsukuni Suenaga
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 791)
DOI
10.1200/JCO.2023.41.4_suppl.791
Abstract #
791
Poster Bd #
M6
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Immune-related adverse effects of long-term PD-1/PD-L1 inhibtor treatment.
First Author: Sarah Kim
Poster
2023 ASCO Gastrointestinal Cancers Symposium
STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer (mCRC).
First Author: J. Randolph Hecht
Poster
2022 ASCO Annual Meeting
Long-term outcomes of adrenal insufficiency (AI) due to anti–PD(L)-1 immune checkpoint inhibitors (ICI) among patients with cancer.
First Author: Ben Nguyen
Poster
2024 ASCO Annual Meeting
Randomized phase III study comparing suspension or continuation of PD-1 pathway blockade for patients with advanced non-small-cell lung cancer (SAVE study: JCOG1701).
First Author: Yasushi Goto